Document is current
Any future updates will be listed below
-
Authors
Osaki, Tatsuya https://orcid.org/0000-0001-7174-0629
Wan, Zhengpeng https://orcid.org/0000-0001-5626-7722
Haratani, Koji https://orcid.org/0000-0002-1767-6854
Jin, Ylliah
Campisi, Marco https://orcid.org/0000-0002-9288-5285
Barbie, David A. https://orcid.org/0000-0002-5422-4275
Kamm, Roger D. https://orcid.org/0000-0002-7232-304X
Sur, Mriganka https://orcid.org/0000-0003-2442-5671
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R01CA190294)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH085802)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH133066)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS130361)
- License Information
-
More Information
Article History
Received: 4 January 2025
Revised: 20 December 2025
Accepted: 4 February 2026
First Online: 18 February 2026
Competing interests
: RDK is a co-founder of AIM Biotech, a company that markets microfluidic technologies and receives research support from Amgen, Abbvie, Boehringer-Ingelheim, Novartis, Daiichi-Sankyo, Roche, Takeda, Eisai, EMD Serono, and Visterra. DAB is a consultant for N of One/Qiagen and Exo Therapeutics, is a founder and shareholder in Xsphera Biosciences, has received honoraria from Merck, H3 Biomedicine/Esai, EMD Serono, Gilead Sciences, Abbvie, and Madalon Consulting, and research grants from BMS, Takeda, Novartis, Gilead, and Lilly and Daiichi Sankyo.
: All methods were performed in accordance with the relevant guidelines and regulations. The use of human iPS cells was reviewed and approved by Picower Institute for learning and memory, Massachusetts Institute of Technology. The human iPS cells were handled in accordance with approved protocols.
